We'll know more about the company's medium-term prospects by the end of the year.

CRISPR Therapeutics stock snapshot and recent performance CRISPR Therapeutics (CRSP) has drawn investor attention after its ...

Innovation often pays off, and this biotech could cement its innovative capabilities in the next few years.

With an approved treatment in commercial stages and new drug candidates generating clinical trial results, this biotech has attracted a big Investor.

CRISPR Therapeutics has significantly lagged the market in recent years due to several factors. However, the biotech has what it takes to be successful in the challenging gene-editing niche. If I had ...

Key market opportunities include advancements in research, medicine, diagnostics, and biotechnology through CRISPR. There is potential for innovative solutions and ethical exploration in gene editing, ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Adam Feuerstein is a ...

CRISPR-Cas9 technology has revolutionized biotechnology by providing an efficient, precise, and versatile tool for genome editing. This RNA-guided system allows scientists to target specific DNA ...

For the first time, a team of researchers from Stellenbosch University (SU) and the Agricultural Research Council has ...

Anurag Chaurasia is a scientist at the Indian Institute of Vegetable Research, Indian Council of Agricultural Research, in Varanasi, India. Increasingly, agricultural scientists in Asia and Africa are ...

Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. Robert F. Kennedy Jr.’s disclosure on Wednesday that he invested in a gene-editing ...

The latest health news highlights Gerresheimer's rejection of a takeover bid from Silgan, researchers' progress with CRISPR for Down syndrome, Eli Lilly's obesity pill traction, Trump's push on ...